NovoCure Limited · NASDAQ:NVCR

NovoCure — Investor Presentation (April 2022)

45 slides from NovoCure's investor presentation, April 2022

  1. Slide 1: Novocure

    Novocure

  2. Slide 2: Forward-looking statements

    novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding a

  3. Slide 3: Tumor Treating Fields

    Tumor Treating Fields INTERRUPT MITOTIC DISRUPT CANCER INDUCE DEATH IN SPINDLE FORMATION CELL DIVISION AFFECTED CANCER CELLS Tumor Treating Fields are alternating electric fields tuned to specific frequencies to disrupt cancer cell division patientforward

  4. Slide 4: Optune is intended as a treatment for adult patients with GBM

    Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

  5. Slide 5: Approaching a critical inflection

    novecure’ 5 4 24,000+ FDA-APPROVED LATE-STAGE PATIENTS TREATED >20 yeals of INDICATIONS PHASE 3 TRIALS GLOBALLY , experlence IN Q1 2022 GLOBAL COMMERCIAL BUSINESS IN 7 OF NET REVENUES THE WORLD'S LEADING MARKETS approaching a critical inflection platform modality ANTI-MITOTIC EFFECT OBSERVED IN EVER

  6. Slide 6: Durable GBM business drives investments in growth

    durable GBM business drives investments in growth net revenues (USD in millions) operating expenses (USD in millions ) a $134.7 $120 ina | 3, 549 ACTIVE PATIENTS ON THERAPY 80% GROSS MARGIN $932 CASH AS OF MARCH 31, 2022 $100 $80 Sa $40 1) so Qi 2020 Qi 2021 ss MNorth America MEEMEA MiJapan ! Greate

  7. Slide 7: A comprehensive strategy for long-term growth

    novecure’ a comprehensive strategy for long-term growth , — , ~~ o ‘ a x / 4 = y / » t 5 3 \ ’ f \ \ ' PAB i , 7 “ARB 4 9. 0 Ry 4 —_) 80868 drive commercial advance deliver adoption clinical trials product innovation in approved in new indications to optimize indications and combinations TTFields th

  8. Slide 8: Drive commercial adoption

    novecure’ drive commercial adoption patientfo rward © 2022Novocure GmbH 8

  9. Slide 9: Glioblastoma: malignant brain cancer

    novecure’ glioblastoma: malignant brain cancer WHO grade 4 49.1% of primary 15,000 cases diagnosed malignant brain tumors? in the U.S. each yeart 14.6 to 16.7 months 65: median age of newly median overall survival® diagnosed GBM patient2 Early detection is nearly 5-10% five-year survival rate imposs

  10. Slide 10: Optune: proven to extend patient survival

    novecure’ Optune: proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) 0) Siacmento” MSRESma 29 NEARLY HALF eo <0.001 ° of people using = 087 GNESI) _ O.SSI0.550026) 43% Optune + TMZ 3 ord Optune (racian 08 from diagnosis 24

  11. Slide 11: Optune: greater exposure increased survival

    novecure’ Optune: greater exposure increased survival MEDIAN OVERALL SURVIVAL BY PERCENT OF TIME ON OPTUNE 25 months P-0.05 22 months P<0.05 Optune + TMZ , = TMZ al 20 months 005 “on OF PATIENTS RECEIVED A SURVIVAL JM te montnsao0s BENEFIT FROM OPTUNE BECAUSE se months THEY USED IT >50% OF THE TIME

  12. Slide 12: Driving commercial growth in GBM

    driving commercial growth in GBM strengthen HCP increase patient COMMERCIAL PENETRATION recommendation demand IN NEWLY DIAGNOSED GBM enter new geographic markets patient

  13. Slide 13: Advance clinical trials

    novecure’ advance clinical trials patientfo rward © 2022 Novocure GmbH 13

  14. Slide 14: Expand label in approved indications

    expand label in approved indications holistic strategy to \ expand | T Fields clinical footprint investigate use in new indications © 2022 Novocure GmbH 14 patient

  15. Slide 15: Phase 2, Phase 3/4, Approved

    PHASE 2 PHASE 3/4 APPROVED completed ✓

  16. Slide 16: Multiple late-stage, randomized pivotal trials set to read out in near-term

    novecure’ multiple late-stage, randomized pivotal trials set to read out in near-term | ENROLLMENT COMPLETE ENROLLMENT COMPLETE | ENGOT-ov50/ z AN war OP Innovaris METIS @ panovas Ovarian Cancer + Evaluating TTFields with * Evaluating TTFields with * Evaluating TTFields after + Evaluating TTFields w

  17. Slide 17: Substantial market expansion opportunity

    substantial market expansion opportunity ANNUAL NUMBER OF U.S. PATIENTS* ~155,000 PATIENTS 43,000 l- —7—1 i] ! i] ! i] 38,000 I 1 I i] [ i] 16,000 ! 1 | 46,000 I I 35% I l penetrated ] in key markets u I 11,200 ! 1 I GBM NSCLC OVARIAN BRAIN METS PANCREATIC’ FUTURE I FROM NSCLC? I —<—=<4 patientforwa

  18. Slide 18: Ongoing research to identify optimal use

    novecure’ ongoing research to identify optimal use --—— ANTI-MITOTIC IMPAIRS DNA REPAIR i Ss em MECHANISMS OF ACTION OF TTFIELDS CELL MEMBRANE ._ PERMEABILITY AUTOPHAGY =. patientforward © 2022 Novocure GmbH 18 Rominiyi O, et al. Tumour treating fields therapy for glioblastoma: current advances and

  19. Slide 19: TTFields plus immunotherapy translating to clinical results

    novocure’ TTFields plus immunotherapy translating to clinical results eliciting immunogenic enhancing antitumor emerging signs of cell death efficacy clinical results Cell surface exposure of calreticulint In combination with anti-PD-1! 2-THE-TOP phase 2 interim clinical data? ee zg wee kK a of prog

  20. Slide 20: ISTs extend TTFields clinical research horizons

    ISTs extend TTFields clinical research horizons LOL NS ik S112 = = a 4 MONTHS MEDIAN PFS IN PATIENTS 2 o7| i" WITH >9 MONTHS OF FOLLOW-UP. & og 5 g ol > OF TTFields/TMZ/PEMBRO re) fa °. 2-THE-TOP study, N=19 2 4. i, 2 4 ] TTFields/TMZ (historical) ° “ od EF-14 study , N=466 OF PATIENTS ACHIEVED PART

  21. Slide 21: Deliver product innovation

    novecure’ deliver product Innovation patientfo rward © 2022 Novocure GmbH 21

  22. Slide 22: Product roadmap to prioritize efficacy and ease of use

    oc oroduct roadmap to prioritize efficacy and ease of use field generator arrays software applications next gen torso device next gen arrays MAXPOINT™ rolling out commercially in development planning software high-intensity head array beta testing underway EF-33 trial underway patient © 2022 Novocur

  23. Slide 23: Greater intensity can lead to increased efficacy

    novecure’ greater intensity can lead to increased efficacy Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical ‘Simulation-Based Analysis of Data from the Phase 3 EF-1 jized Trial FIELD TUMOR TREATING TIME ON —_— THERAPY INTENS

  24. Slide 24: Increased intensity led to greater cell death in vitro

    novecure’ increased intensity led to greater cell death in vitro — U373 B --- U87-MG glioma 2 = AL72 8 —_ NCI-H520 lung ° 3s ~~ MSTO-24t mesothelioma 2 => NCI-H2052 o o — _ KATOIII F s astric FE “> AGS 9 2 — _ OVCAR-3 : 3 --- Caov-3 ovarian Y ~7_A2780 0 , , , — HeLa F cervical 0.0 0.4 0.8 1.2 1.6 >

  25. Slide 25: Next gen arrays designed for more efficient delivery

    novecure’ next gen arrays designed for more efficient delivery ARRAY PERFORMANCE Average Current (2-Channels) 2,250 NEXT GEN i CO 1,750 CURRENT ARRAY 2,000 Current (mAmps) 1,500 1250 S. SPP PP PPP PPP PP LL PF PPP APP FP PP LPP? PP PPP PP MPL FP KOPP sl Time Lapsed (Hours) PAP AV APS AVERAGE AVERAGE

  26. Slide 26: Next generation array increases coverage and dose

    next generation array increases coverage and dose 10 V/cm NEXT GEN ARRAYS AP channel, 1,988 mAmps CURRENT ARRAYS AP channel, 1,588 mAmps Data on file. Simulation of electric field distribution in healthy brain model.

  27. Slide 27: Catalyst-rich through 2024

    novecure’ catalyst-rich through 2024 2021 2022 2023 2024 2024 ANTICIPATED PIVOTAL DATA LUNAR phase 3 interim analysis LUNAR phase 3 enrollment complete INNOVATE phase 3 enrollment complete HEPANOVA-2 phase 2 data EF-31 gastric phase 2 enrollment complete patientforward LUNAR phase 3 data INNOVATE-3

  28. Slide 28: Together with our patients, we strive to extend survival

    together with our patients, 4 we Strive to extend survival in some of the most aggressive forms of cancer patientforward

  29. Slide 29: Appendix

    novecure’ a oe Appendix patientforward

  30. Slide 30: Increasing acceptance for TTFields across the global oncology community

    novecure’ increasing acceptance for TTFields across the global oncology community @ Ourreach @ ISTs/inovivo/inovitro research @ Offices @ Clinical development TUMOR TREATING FIELDS ECOSYSTEM patientforward © 2022Novocue GmbH 30

  31. Slide 31: Therapy is frequency-tuned to target dividing cancer cells

    novecure’ therapy is frequency-tuned to target dividing cancer cells a TUMOR TREATING FIELDS 150 kHz 200 kHz Normal ntestine Intestin | | 50kHz 100 kHz 150 kHz 200 kHz 10 kHz 250 kHz Low Frequencies Intermediate High Frequencies DNA Damage cardiac defibrillator Frequencies radiofrequency ablation io

  32. Slide 32: Ongoing LUNAR trial in non-small cell lung cancer

    novecure’ ongoing LUNAR trial in non-small cell lung cancer LUNAR PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN ae mee CT q6wuntil an> (pes survival progression on inhibitor/docetaxel progres: follow-up visits lll@aeup or after platinum- jai baseline —— based therapy evaluation immune checkpo

  33. Slide 33: Ongoing INNOVATE-3 trial in ovarian cancer

    novecure’ ongoing INNOVATE-S3 trial in ovarian cancer INNOVATE-3 PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! & TTFields + weekly [i CT/MRI scan q8w _ survival 7 s paclitaxel until progressi follow-up assis vals s weekly paclitaxel CT/MRI scan q8w [i survival S YP until progression follow-u

  34. Slide 34: Ongoing METIS trial in brain metastases

    novecure’ ongoing METIS trial in brain metastases METIS PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! 6 Ee. Tumor Treating [iim MRI q2m until ro 4 radiosurger Fields rogression screening and ji 8 a sey) pres baseline evaluation € 8 a _ MRI a2 til a] NY stereotactic a F An q2m unti g radiosur

  35. Slide 35: Ongoing PANOVA-3 trial in pancreatic cancer

    ongoing PANOVA-S trial in pancreatic c PANOVA-3 PHASE 3 PIV , OPEN-LABEL, RANDOMIZED TRIAL DESIGN* TTFields + nab-paclitaxel + gemcitabine CT q8w until progression post-PD follow up visit screening and baseline evaluation nab-paclitaxel + gemcitabine CT q8w until progression post-PD follow up visit

  36. Slide 36: Ongoing TRIDENT trial in newly diagnosed GBM

    novecure’ ongoing TRIDENT trialin newly diagnosed GBM TRIDENT PHASE 4 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN? TTFields + RT TTFields + MRI q8w until + TMZ maintenance TMZ progression survival follow-up screening and baseline evaluation TTFields + MRI q8w until survival Ba spb, maintenance TMZ

  37. Slide 37: Ongoing phase 2 pilot trial in gastric cancer in Greater China

    novocure ongoing phase 2 pilot trial in gastric cancer in Greater China in partnership with Zai Lab EFFICACY OF TTFIELDS AND FOLFOX COMBINATION TREATMENT? AGS overall effect 150. os ™ Chemotherapy $2 100 wm TrFltds + Chemotherapy &3 OE $8 so Eo 28 ‘The overall effect of TTFields/FOLFOX combination t

  38. Slide 38: Ongoing KEYNOTE B36 trial in non-small cell lung cancer

    novecure’ ongoing KEYNOTE B36 trial in non-small cell lung cancer KEYNOTE B36 PHASE 2 PILOT TRIAL DESIGN* screening and TTFields (150 kHz) CT/MRI scan q9w until post-progression survival baseline evaluation JJ + pembrolizumab progression or 24 mo follow-up follow-up @ KEYNOTE B36 Lung Cancer STUDY D

  39. Slide 39: Enrollment ongoing to test new high-intensity array concept in EF-33 trial

    novecure’ enrollment ongoing to test new high-intensity array concept in EF-535 clinical trial PRECLINICAL RATIONALE PHASE 2 PILOT TRIAL DESIGN TESTING SAFETY AND EFFICACY OF TTFIELDS DELIVERED THROUGH HIGH-INTENSITY ARRAYS IN RECURRENT GBM? STANDARD 9-DISC HIGH-INTENSITY 14-DISC TRANSDUCER ARRAYS T

  40. Slide 40: Growing evidence supports broad applicability in combination with other cancer therapies

    novecure’ growing evidence supports broad applicability in combination with certain other cancer therapies TUMOR TREATING FIEL WITH RADIATION THERAPY: WITH CERTAIN WITH CERTAIN CHEMOTHERAPIES2 IMMUNOTHERAPIES3 - . 300 100 ” 150: — Paclitaxel 3 = 90 2 —s- Paclitaxel + TTFields © aon $ 80 as e = 70 ££

  41. Slide 41: Kaplan-Meier OS

    Kaplan-Meier OS Kaplan-Meier OS

  42. Slide 42: TTFields can elicit immunogenic cell death

    novecure’ TTFields can elicit immunogenic cell death through induction of various forms of stress in vitro Triggers apoptosis followed by extracellular release of HMGB1! May mediate cell surface Induces autophagy dependent exposure of calreticulin! reduction in intracellular ATP levels! g $s 8 8 N S

  43. Slide 43: In vivo data suggest TTFields together with anti-PD-1 therapy resulted in increased tumor control

    novecure’ in vivo data suggest TTFields together with anti-PD-1 therapy resulted in increased tumor control Lewis lung carcinoma S00 TTFields r ——1 ; 520 — _ a-PD-1 (250y1g/mouse, i.p.) z LLC; Orthotopic | ! | 3 100 | ! ! e 0 6 7 10 13 15 Q g Ss Days after tumor inoculation — we « ae 3 & og murine c

  44. Slide 44: Optune Lua and Optune indications for use and important safety information

    novecure’ Optune Lua™ and Optune® indications for use and important safety information INDICATIONS » Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of

  45. Slide 45: Warnings and precautions

    novecure’ Optune Lua™ and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event

Novocure — Investor Presentation (April 2022) on 6ix